Participate in a Study
hello world!
Pediatric Clinical Trials

Pediatric clinical research
designed for children and families

Science 37 supports pediatric trials through direct-to-patient delivery models designed to reduce burden for families while maintaining rigorous oversight, safety, and protocol adherence. 
Medical record-qualified, site-ready referrals that reduce site burden and accelerate randomization.

Proven pediatric experience:

20+ pediatric clinical trials

supported to date

Phases I-III and observational

research experience

Top enrolling site

in a Phase III Fragile X Syndrome study

94% retention

in a difficult-to-retain pediatric rare disease population

Why Pediatric Trials Require a Different Approach

Pediatric research presents unique clinical and operational challenges. Patient populations are often smaller and geographically dispersed. Caregivers must coordinate participation around school schedules, work obligations, and other family responsibilities. In many conditions, children may experience sensory sensitivity, anxiety, or behavioral challenges that make traditional site visits difficult.

Traditional site-based models can unintentionally limit access and increase dropout risk. Science 37 was built to expand access while protecting quality. Our pediatric capabilities are designed specifically for children, adolescents, and the families who support them.
BouaSy Huneycutt, MD
Medical Director,
Pediatric Medicine

A Dedicated Pediatric Department

Science 37’s Pediatric Department centralizes pediatric clinical and operational expertise under specialized leadership and delivery infrastructure built for children and adolescents.
 
Our pediatric programs are guided by Dr. BouaSy Huneycutt, Medical Director, Pediatric Medicine at Science 37. Dr. Huneycutt is board-certified in both Pediatrics and Internal Medicine, bringing extensive clinical experience across developmental-behavioral pediatrics, adolescent medicine, dermatology, respiratory disease, and pediatric gastroenterology.

This is not a generalized staffing model. It is a specialized pediatric department designed to support sponsors in navigating the complexity of pediatric development programs.

Our Pediatric Model: Three Pillars

Science 37 guarantees every referral is pre-screened and study-qualified, so sponsors and sites can focus on ready-to-go patients.

01

Specialized Care and Reduced Family Burden

At the center of our pediatric model is a nationwide network of pediatric-trained, research-qualified clinicians supported by centralized oversight and standardized processes.

By conducting appropriate study activities in the home or alternative settings (e.g., schools), we can:

  • Reduce travel burden for families
  • Minimize disruption to school and work schedules
  • Support children in familiar, lower-stress environments
  • Improve caregiver engagement and retention

Our approach prioritizes continuity, comfort, and clarity for families without compromising protocol execution.

02

Universal Access and Enrollment Performance

Pediatric trial enrollment is frequently constrained by geography. Many eligible patients live outside the catchment areas of traditional research sites, particularly in rare diseases.  Science 37 expands access beyond physical site boundaries, enabling sponsors to reach pediatric participants regardless of location.

This model supports:

  • Broader geographic inclusion
  • Participation for families outside major academic centers
  • Increased identification of eligible patients
  • Strong enrollment performance in complex indications

By removing geographic limitations, sponsors can design pediatric trials around patient needs rather than site density.

03

Quality, Oversight, and Compliance

A direct-to-patient approach does not reduce oversight. In the Science 37 model, oversight is centralized, standardized, and embedded across delivery.

Our pediatric capabilities include:

  • Medical oversight
  • GCP- and SOP-driven training before patient interaction
  • Standardized documentation and workflow management
  • Structured safety escalation pathways
  • Protocol adherence support across visit types
  • Centralized oversight of clinical delivery
  • FDA-inspected operational frameworks

Our objective is clear: expand access without compromising data integrity, compliance, or safety.

Pediatric Capabilities

Science 37 supports pediatric sponsors across the full lifecycle of clinical trial execution.
Science 37 guarantees every referral is pre-screened and study-qualified, so sponsors and sites can focus on ready-to-go patients.

Caregiver-Centered Participant Experience

Clear communication, structured scheduling support, and a study experience designed around family realities. 

Direct-to-Patient Visit Delivery

Home or school-based visits aligned to protocol requirements.

Consent and Assent Workflows

Support for caregiver consent and age-appropriate assent processes aligned to study design and regulatory requirements.

Pediatric-Trained Clinical Network

Research-qualified clinicians and nurses experienced in pediatric study participation and family-centered care.

Pediatric Safety and Medical Oversight

Defined monitoring processes and escalation pathways structured for pediatric populations.

Recruitment and Enrollment Enablement

Sponsor-aligned outreach strategies that support inclusive and geographically expanded enrollment.

Pediatric Experience Across Therapeutic Areas

Science 37 has supported 20+ pediatric trials across multiple therapeutic areas and study phases, including interventional and observational research.

Therapeutic experience includes:

  • Cardiovascular
  • Central Nervous System
  • Endocrinology
  • Gastroenterology
  • Hematology
  • Immunology
  • Infectious Disease
  • Respiratory
  • Urology
  • Rare Disease

Study phase experience includes Phase I, Phase II, Phase III, and observational studies.

This breadth enables sponsors to apply a specialized pediatric model across diverse development programs.

Case Study: Fragile X Syndrome (FXS)

(Phase III, Rare Disease, Neurology)
Science 37 guarantees every referral is pre-screened and study-qualified, so sponsors and sites can focus on ready-to-go patients.

Challenge

Families of Fragile X patients often face significant caregiving responsibilities. Sensory sensitivity and discomfort in unfamiliar clinical environments can increase stress and attrition risk. Frequent specimen collection and caregiver-administered dosing adds additional burden.

Results

25%

of total study participants enrolled

94%

retention in a difficult-to-retain population

Solution

Science 37 enabled direct-to-patient participation tailored to this pediatric disease population. Pediatric-trained, research-qualified clinicians and nurses supported comfort and protocol adherence in the home environment. Collaboration with advocacy organizations strengthened awareness and engagement.

Top

enrolling site in the trial

Ready to Accelerate Your Pediatric Program?

Science 37 is prepared to support sponsors with a specialized model designed to expand access, reduce family burden, and deliver compliant, high-quality trial execution.
© 
2026
 Science 37 | All Rights Reserved